BioSpace News Archive

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or “the Company”) today announced the closing of its previously announced public offering of 76,923,077 shares of its common stock (or common stock equivalents in lieu thereof) at a price to the public of $0.325 per share of common stock (or common stock equivalent

One of 25 experts selected nationwide, Neil L. Pruitt Jr. , chairman and CEO of PruittHealth, has been appointed to serve on a new, independent commission set to begin a comprehensive assessment of the nursing home response to the COVID-19 pandemic.

Agency Cited Travel Restrictions and Inability to Conduct Onsite Inspections to Resolve Observations at Manufacturing Partner Facilities

HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, announced that Dr. Sander van Deventer has resigned as a Non-Executive Director of the Company’s Board of Directors and Audit Committee.

Genetworx Laboratories, a leading innovative molecular diagnostic testing laboratory, announced today that the company is now performing COVID-19 antibody testing, in addition to diagnostic testing, for the virus.

Phelan-McDermid Syndrome is thought to be one of the causes of Autism Spectrum Disorder Patient stratification to be carried out prior to clinical study with Oryzon’s vafidemstat LSD1 inhibition may open the way to precision medicine in certain subtypes of CNS disorders MADRID, Spain and CAMBRIDGE, Mass., June 19, 2020 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in dis

Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to OV101 (gaboxadol) for the treatment of Angelman syndrome. OV101 is believed to be the only delta (δ)-selective GABA A receptor agonist in development and is currently be

Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020 at 10:00 a.m. ET. A live webcast of the presentation will be available at http://ir.retrophin.com/events and an archived replay will be accessible for up to 30 days. About Retrophin Retrophin is a biopharmaceutical company specializing in identif

Happiness Biotech Group Limited (the “Company” or Nasdaq: HAPP), an innovative China -based nutraceutical and dietary supplements producer, announced today that the Company has obtained the CE Certification for the Company’s COVID-19 anti-body testing kits on June 5, 2020 and samples of these testing kits have been shipped to count

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the “Company”) , is a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions. As part of this program, the Company is developing therapies for patients infected with the SARS-CoV-2 virus (“COVID-19").